Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

Delayed Quote. Delayed  - 07/28 10:00:00 pm
31.47 USD   +0.10%
07/27 Teva, Allergan win U.S. antitrust approval for generics deal
07/21 IMPAX LABORATOR : Names Douglas S. Boothe President of Generics Divi..
07/12DJTeva Raises Guidance
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2013 | 01:35pm CEST

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications
www.impaxlabs.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMPAX LABORATORIES INC
07/27 Teva, Allergan win U.S. antitrust approval for generics deal
07/21 IMPAX LABORATORIES INC : Change in Directors or Principal Officers (form 8-K)
07/21 IMPAX LABORATORIES : Names Douglas S. Boothe President of Generics Division
07/14 IMPAX LABORATORIES : to Report Second Quarter 2016 Results on August 9, 2016
07/12DJTeva Raises Guidance
07/07 IMPAX LABORATORIES : to Report Second Quarter 2016 Results on August 9, 2016
07/06 IMPAX ASSET MANAGEMENT : Net Inflows Strong, Assets Under Management Up
06/23 IMPAX ASSET MANAGEMENT : Natural Power advises Impax on Irish wind financing dea..
06/22 IMPAX ASSET MANAGEMENT : Natural Power advises Impax on Irish wind financing dea..
06/22DJBusiness Watch -- WSJ -2-
More news
Sector news : Pharmaceuticals - NEC
07:45aDJSANOFI : Profit Down as Diabetes Drug Sales Slip
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/28DJALEXION PHARMACEUTICALS : Cuts Profit Guidance
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/04 FINDING VALUE WITH THE PIOTROSKI F-S : Part 3
06/22 IMPAX LABS : Large Acquisition Used To Hide Major Guide-Down
06/21 Midday Gainers / Losers
06/21 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/21 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
Advertisement
Financials ($)
Sales 2016 994 M
EBIT 2016 212 M
Net income 2016 108 M
Debt 2016 49,4 M
Yield 2016 -
P/E ratio 2016 39,94
P/E ratio 2017 13,39
EV / Sales 2016 2,39x
EV / Sales 2017 2,13x
Capitalization 2 323 M
More Financials
Chart IMPAX LABORATORIES INC
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Full-screen chart
Technical analysis trends IMPAX LABORATORIE...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 34,9 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
George Frederick Wilkinson President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Vishal K. Gupta CSO, Senior Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMPAX LABORATORIES INC-26.40%2 323
JOHNSON & JOHNSON21.16%342 345
PFIZER INC.13.60%222 398
ROCHE HOLDING LTD.-9.99%215 597
NOVARTIS AG-5.30%214 061
MERCK & CO., INC.10.62%161 736
More Results